An FDA advisory committee has voted, narrowly, to add six popular peptides, including BPC-157 and TB-500, to the federal list of raw ingredients that compounding pharmacies are allowed to use. Nothing a med spa or compounding pharmacy may lawfully offer changed that day. The vote was a recommendation, and the FDA’s own scientists opposed all seven peptides under review.
The committee advises the FDA. It does not set policy, and the agency can reject what the panel recommends. What the vote signals to compounding pharmacies, medical spas, and anti-aging clinics is that the rules may be loosening, while the line between unapproved experimental substances and compliant compounded medications sits where it always has.
What the Panel Voted On
Following a two-day meeting of the FDA’s Pharmacy Compounding Advisory Committee on July 23 and 24, 2026, the panel evaluated seven prominent peptides. The committee backed six and rejected one, in each case overriding FDA scientific staff, who recommended against all seven. The compounding pharmacy and industry group that originally petitioned FDA to add these substances withdrew their requests before the meeting, and FDA brought them to the committee anyway.
Each peptide was reviewed in two chemical forms, free base and acetate, a distinction that matters to chemists rather than to your compliance analysis. The six recommended peptides, and the uses FDA evaluated for each, are:
- BPC-157: Evaluated for ulcerative colitis.
- KPV: Evaluated for wound healing and inflammatory conditions.
- TB-500: Evaluated for wound healing.
- MOTS-c: Evaluated for obesity and osteoporosis.
- Epitalon: Evaluated for insomnia.
- Semax: Evaluated for cerebral ischemia (reduced blood flow to the brain), migraine, and trigeminal neuralgia (severe facial nerve pain).
The panel rejected Emideltide (delta sleep-inducing peptide / DSIP), which had been nominated for treating opioid withdrawal, chronic insomnia, and narcolepsy, on a 6-7 vote with one abstention.
Note: This vote pertains solely to the 503A Bulk Drug Substances List for pharmacy/physician compounding and has no bearing on 503B outsourcing facilities, which operate under a separate bulks list and clinical-need standard.
Why This One List Decides Whether Your Peptides Are Legal
For years, many of these peptides have existed in a regulatory gray zone. Providers in integrative, functional, and anti-aging medicine prescribe them every day, but no one has settled whether pharmacies may lawfully make them. That question turns on the 503A Bulks List, which is the FDA’s roster of raw ingredients a compounding pharmacy is permitted to use.
On September 29, 2023, the FDA placed more than a dozen popular peptides, including BPC-157, TB-500, epitalon, and semax, into “Category 2” of the interim bulk substances list. Citing critical safety concerns regarding potential unwanted immune responses, issues with structural aggregation, and a deficit of human safety data, the FDA barred compounding pharmacies from legally manufacturing them.
That picture shifted in April 2026. FDA removed twelve peptides, including all seven reviewed in July, from Category 2 after the parties that petitioned for them withdrew those requests. Removal from Category 2 is not the same as permission. These peptides are still not on the 503A Bulks List, and they do not get the temporary pass FDA gives Category 1 substances, where the agency has said it will not act against pharmacies that compound with them while their status is worked out. Category 2 meant barred from compounding. These peptides now sit in neither category, which is why the July vote drew the attention it did.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), human drug products compounded by a licensed pharmacist or physician are exempt from three federal mandates:
- Current Good Manufacturing Practice (cGMP) standards
- Labeling with adequate directions for use
- The new drug approval process
These exemptions are what make patient-specific compounding economically and logistically viable. However, a compounded medication only qualifies for these exemptions if the bulk substance used to create it meets one of three strict criteria. It must comply with an official USP or National Formulary monograph, be a component of an existing FDA-approved drug, or appear on the FDA’s 503A Bulk Drug Substances List.
Because BPC-157, TB-500, MOTS-c, and the other reviewed peptides do not have monographs and are not part of approved commercial drugs, their legal survival in the wellness industry hinges on making it onto this regulatory list.
Key Takeaways for Med Spas, Clinicians, and Compounding Pharmacies
1. This Vote Changed Nothing Yet
The advisory committee’s vote is a recommendation, not a final rule. The FDA has the final authority to accept or reject these findings, and a formal rule-writing process with a public comment period would still be required before anything is added. That process usually takes more than a year. Until it concludes, or FDA extends a temporary pass in the meantime, compounding with these ingredients does not qualify for the Section 503A exemptions. The pharmacy that compounds a peptide and the provider who prescribes it face different risks, and you should know which one you are before you act on this vote.
2. The Panel Remained Sharply Divided
The narrow votes for Epitalon (7-5 with one abstention), Semax (8-5), and BPC-157, KPV, and TB-500 (8-6 with one abstention) came against a documented record of safety and evidence gaps. FDA seated eight temporary voting members shortly before the meeting, and on three of the four substances heard the first day, all eight voted yes while six other members voted no. Providers should expect the FDA to move cautiously, and any final rule may narrow the uses it permits or attach conditions.
3. Part of a Growing Regulatory Trend
This scientific review is part of a broader push by the FDA to impose order on compounding, particularly with respect to peptides and biologics that have grown quickly in popularity across wellness, sports medicine, and longevity settings. State boards of medicine and pharmacy are scrutinizing how medical spas and wellness clinics actually operate, including whether the products they market as wellness therapies come from a lawful source.
4. A Favorable Vote Does Not Put Product on the Shelf
Even on the most favorable path, the rule-writing process typically runs well over a year. Much of the raw peptide material circulating today is sold as research grade, meaning it is for laboratory use only and cannot lawfully go into a product dispensed to a patient. Pharmaceutical-grade material does not yet exist at commercial scale for several of these peptides. A practice building a business plan around near-term availability should account for that lag.
5. Your Own Liability Did Not Change
The vote addressed one question, which is whether a pharmacy may lawfully compound with these ingredients. It said nothing about whether you met the standard of care, documented informed consent, stayed inside your scope of practice, advertised truthfully, or were permitted to dispense and mark up a drug in your office. Those obligations live in state licensing law, malpractice law, and consumer protection law, and no FDA advisory vote touches any of them. A practice administering research-grade material has a problem no change to the federal list would cure, because that problem is a licensing and negligence problem rather than a compounding one.
What to Do This Week
Review your peptide protocols now rather than after a rule issues. Ask your pharmacy where its ingredients come from and whether it compounds under Section 503A. Check the status of every peptide on your menu. Make sure your consent forms say plainly that these products are compounded and carry no FDA-approved labeling. And do not build next year’s service menu on a vote the FDA has not acted on.
How this applies to a particular practice depends on its structure and the state it operates in. If you are evaluating a peptide offering, or you want your existing protocols measured against where the federal rules stand today, the healthcare regulatory team at Lengea Law can help. Contact us to set up a conversation.
This post is general information about a developing regulatory matter and is not legal advice. Confirm current regulatory status before acting.